KR20210131597A - Composition for preventing hair loss and promoting hair growth comprising runcinatside - Google Patents
Composition for preventing hair loss and promoting hair growth comprising runcinatside Download PDFInfo
- Publication number
- KR20210131597A KR20210131597A KR1020200049883A KR20200049883A KR20210131597A KR 20210131597 A KR20210131597 A KR 20210131597A KR 1020200049883 A KR1020200049883 A KR 1020200049883A KR 20200049883 A KR20200049883 A KR 20200049883A KR 20210131597 A KR20210131597 A KR 20210131597A
- Authority
- KR
- South Korea
- Prior art keywords
- runcinatside
- hair
- composition
- present
- hair growth
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 230000003779 hair growth Effects 0.000 title claims abstract description 38
- 230000003658 preventing hair loss Effects 0.000 title claims abstract description 24
- 230000001737 promoting effect Effects 0.000 title claims abstract description 23
- 235000013305 food Nutrition 0.000 claims abstract description 42
- 239000002537 cosmetic Substances 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 239000000126 substance Substances 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 27
- 210000004209 hair Anatomy 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 244000137987 Terminalia ferdinandiana Species 0.000 claims description 4
- 235000017403 Terminalia ferdinandiana Nutrition 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- -1 patches Substances 0.000 claims description 4
- 210000004761 scalp Anatomy 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims 1
- 229940040145 liniment Drugs 0.000 claims 1
- 235000015927 pasta Nutrition 0.000 claims 1
- 239000002453 shampoo Substances 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 39
- 150000001875 compounds Chemical class 0.000 abstract description 29
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 15
- 229960003632 minoxidil Drugs 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 13
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 13
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 13
- 201000004384 Alopecia Diseases 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 230000003676 hair loss Effects 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 208000024963 hair loss Diseases 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 235000013350 formula milk Nutrition 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229930014626 natural product Natural products 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229940116598 kakadu plum extract Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000031774 hair cycle Effects 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 235000013555 soy sauce Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000723436 Chamaecyparis obtusa Species 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000003024 Diffuse alopecia Diseases 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical class OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 244000181366 Polygonum runcinatum Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000003645 female-pattern hair loss Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000000642 hair follicle dermal papilla cell Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000003273 male-pattern hair loss Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000004918 root sheath Anatomy 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 탈모 방지 및 발모 촉진 효과가 있는 런시나트사이드(runcinatside)를 포함하는 조성물에 관한 것이다.The present invention relates to a composition comprising runcinatside, which has effects of preventing hair loss and promoting hair growth.
인간의 모발은 인체에 산재되어 외부의 자극으로부터 충격을 흡수하는 쿠션의 역할과 직사광선, 추위, 마찰 등과 같은 외부의 위험요인들로부터 신체를 보호하고 중금속인 비소(As), 수은(Ag), 아연(Zn) 등을 체외로 배출하는 역할을 하고 있다. 현대 사회는 개개인의 개성을 나타내기 위한 모발의 장식적 기능이 중요하게 대두되고 있으므로, 탈모 증상은 현대인들의 고민거리 중 하나이다. Human hair is scattered throughout the body and acts as a cushion to absorb shock from external stimuli, protects the body from external risk factors such as direct sunlight, cold, friction, etc. (Zn), etc., plays a role in excreting it from the body. In modern society, the decorative function of hair to express individual individuality is emerging as important, so the symptom of hair loss is one of the concerns of modern people.
탈모는 정상적으로 모발이 존재해야 하는 부위에 모발이 없는 상태를 말하거나, 성장을 멈춘 모발이 자연스럽게 빠지는 현상을 의미한다. 모발은 보통 하루에 50~100개 이상 정도가 빠지며, 머리가 빠지는 숫자가 많을수록 탈모증이라고 여겨진다. Hair loss refers to a state in which there is no hair in the area where hair should normally exist, or refers to a phenomenon in which hair that has stopped growing naturally falls out. Generally, more than 50 to 100 hairs fall out per day, and the higher the number of hair loss, the more it is considered alopecia.
탈모의 원인은 매우 다양하며, 대머리의 발생에는 유전적 원인과 남성 호르몬인 안드로겐(androgen)이 중요한 인자로 생각되고 있다. 여성형 탈모의 일부는 남성형 탈모와 같은 경로로 일어나는 것으로 추정되고 있고, 원형 탈모증은 자가 면역 질환의 하나로 생각되고 있다. 또한, 휴지기 탈모증의 경우 내분비 질환, 영양 결핍, 약물 사용, 출산, 발열, 수술 등 심한 신체적, 정신적 스트레스로 인해 발생되며, 이는 일시적인 탈모로 모발의 일부가 생장 기간을 다 채우지 못하고 휴지기 상태가 되어 야기되는 것으로 여겨진다.The causes of hair loss are very diverse, and genetic causes and androgens, which are male hormones, are considered to be important factors in the occurrence of baldness. It is estimated that a part of female pattern hair loss occurs in the same route as male pattern hair loss, and alopecia areata is considered to be one of the autoimmune diseases. In addition, in the case of telogen alopecia, it is caused by severe physical and mental stress such as endocrine disease, nutritional deficiency, drug use, childbirth, fever, and surgery. is believed to be
이러한 탈모 증상의 예방 및 치료를 위해 다양한 시도가 이루어져 왔는데, 두피피판술, 탈모부위축소술, 조직확장술, 자가모발 이식술 등의 외과적 방법이 있으며, 외과적 방법 이외에도 다양한 외용제를 통해 탈모 방지 및 예방 방법도 있다. 예컨대, 천연물 등의 한방 추출물을 이용한 탈모 방지 및 발모촉진제 등을 이용하기도 한다.Various attempts have been made to prevent and treat these hair loss symptoms, and there are surgical methods such as scalp flap surgery, hair loss site reduction, tissue expansion, and autologous hair transplantation. have. For example, a hair loss prevention and hair growth promoting agent using oriental herbal extracts such as natural products are also used.
그러나, 탈모 증상의 예방 및 치료를 위한 외과적 수술과 같은 방법은 단기간에 우수한 효과를 볼 수 있지만, 수술에 대한 환자의 경제적, 정신적 부담이 크다는 문제점이 존재한다. 또한, 합성제제로서의 외용제는 성욕감퇴, 발기부전과 같은 성기능 감퇴 등의 부작용을 발생시키거나, 또는 여성에게 상기 합성제제가 노출 시 기형아 출산이라는 심각한 위험 요소가 있다. 한편, 천연물 등을 이용한 탈모 예방 및 치료제는 부작용이 감소되기는 하지만 치료 효과가 만족스럽지 못한 경우가 많았다.However, methods such as surgery for the prevention and treatment of hair loss symptoms can have excellent effects in a short period of time, but there is a problem that the economic and mental burden of the patient is large for the operation. In addition, external preparations as synthetic preparations cause side effects such as decreased sexual function such as decreased libido and erectile dysfunction, or there is a serious risk factor of birth defects when the synthetic preparations are exposed to women. On the other hand, although the side effects of hair loss prevention and treatment using natural products were reduced, the treatment effect was not satisfactory in many cases.
본 발명자들은 상기 종래 기술의 문제점을 인지하고, 탈모를 방지하고 발모를 촉진하는 효과가 우수한 약학적 조성물, 식품 조성물 또는 화장료 조성물에 적합한 유효성분을 장기간 연구해왔다. 그 결과, 부작용은 적으면서 치료 효과가 우수한 유효성분을 발명하여 본 발명을 완성하게 되었다.The present inventors have recognized the problems of the prior art, and have been studying for a long time an active ingredient suitable for a pharmaceutical composition, a food composition or a cosmetic composition having an excellent effect of preventing hair loss and promoting hair growth. As a result, the present invention was completed by inventing an active ingredient having excellent therapeutic effects with few side effects.
본 발명에 따른 조성물의 유효성분은 하기 화학식 1로 표시되는 런시나트사이드(runcinatside) 화합물 또는 이의 허용가능한 염이다.The active ingredient of the composition according to the present invention is a runcinatside compound represented by the following Chemical Formula 1 or an acceptable salt thereof.
[화학식 1][Formula 1]
상기 화학식 1로 표시되는 런시나트사이드의 화합물명은 3,3'-디메틸엘라그산-4'-O-(6''-갈로일)-β-D-글루코사이드(3,3'-dimethylellagic acid-4'-O-(6''-galloyl)-β-D-glucoside)이다.The compound name of runcinatside represented by
또한, 본 발명에 따른 상기 런시나트사이드 화합물은 염의 형태로 사용될 수 있다. 상기 염으로는 약학적으로, 식품학적으로, 또는 화장품학적으로 허용가능한 유리산(free acid)에 의하여 형성된 산 부가염이 바람직하며, 상기 유리산으로는 유기산과 무기산을 사용할 수 있다. 상기 유기산의 예에는 구연산, 초산, 젖산, 주석산, 말레인산, 푸마르산, 포름산, 프로피온산, 옥살산, 트리플로오로아세트산, 벤조산, 글루콘산, 메타술폰산, 글리콜산, 숙신산, 4-톨루엔술폰산, 글루탐산, 아스파르트산 등이 포함되지만, 이에 제한되는 것은 아니다. 상기 무기산에는 염산, 브롬산, 황산, 인산 등이 포함되지만, 이에 제한되는 것은 아니다.In addition, the runcinatside compound according to the present invention may be used in the form of a salt. The salt is preferably an acid addition salt formed with a pharmaceutically, food, or cosmetically acceptable free acid, and an organic acid and an inorganic acid may be used as the free acid. Examples of the organic acid include citric acid, acetic acid, lactic acid, tartaric acid, maleic acid, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, metasulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, glutamic acid, aspartic acid and the like, but are not limited thereto. The inorganic acid includes, but is not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, and the like.
본 발명의 다른 구현예에 있어서, 상기 런시나트사이드의 농도는 1 내지 10%, 예를 들어 1%, 3% 또는 5%일 수 있다. In another embodiment of the present invention, the concentration of runcinatside may be 1 to 10%, for example 1%, 3% or 5%.
본 발명에 따른 런시나트사이드 화합물은 천연으로부터 분리하거나 또는 제조할 수 있다. 예를 들어, 카카두플럼(Kakadu plum : 학명 Terminalia ferdinandiana) 추출물로부터 분리 및 정제하여, 런시나트사이드 화합물을 수득할 수 있다. 이는 세포에 독성을 유발하지 않으므로 체내에서 안정한 특징이 있어, 경구 약물 또는 식품의 소재로도 사용할 수 있는 이점이 있다. The runcinatside compound according to the present invention may be isolated from nature or may be prepared. For example, by separation and purification from the Kakadu plum (Scientific name: Terminalia ferdinandiana) extract, the runcinatside compound can be obtained. Since it does not cause toxicity to cells, it is stable in the body and has the advantage that it can be used as a material for oral drugs or food.
상기 카카두플럼은 시중에 판매하는 것이라면 모두 사용할 수 있으며, 재배한 것 또는 채취한 것도 사용 가능하다. 용어 "카카두플럼 추출물"은 카카두플럼으로부터 수득한 추출물을 의미한다. 용어 "추출물"은 생약을 적절한 추출용매로 추출하고 추출용매를 증발시켜 농축한 제제를 의미하는 것으로, 추출처리에 의해 얻어지는 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 이들의 조정제물 또는 정제물일 수 있다. 본 발명에 따른 카카두플럼 추출물은 당업계에 공지된 일반적인 추출방법을 이용하여 제조할 수 있으며, 예를 들어 열탕 추출, 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출 등의 방법을 사용할 수 있다. 용매로 추출하기 전에 충분히 건조시킨 것을 사용하는 것이 바람직하다. 일 구체예로서, 건조된 카카두플럼은 알코올, 예를 들어 에탄올 또는 메탄올로 환류 추출하며, 추출 횟수는 1~5회, 바람직하게는 3회 추출한다. The Kakadu plum can be used as long as it is commercially available, and it is also possible to use cultivated or collected ones. The term "kakadu plum extract" means an extract obtained from kakadu plum. The term "extract" refers to a preparation obtained by extracting a crude drug with an appropriate extraction solvent and evaporating the extraction solvent to concentrate, an extract obtained by extraction treatment, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, and a crude product thereof Or it may be a purified product. The Kakadu plum extract according to the present invention can be prepared using a general extraction method known in the art, for example, methods such as hot water extraction, hot water extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction can be used. . It is preferable to use what has been sufficiently dried before extraction with a solvent. In one embodiment, the dried kakadu plum is extracted under reflux with alcohol, for example, ethanol or methanol, and the number of extractions is 1 to 5 times, preferably 3 times.
또한, 상기 카카두플럼 추출물은 카카두플럼에 유기용매를 첨가하여 추출한 추출물일 수 있으며, 정제수를 포함한 물, 메탄올, 에탄올, 부탄올 등의 탄소수 1 내지 4의 저급 알코올 또는 이들의 혼합용매로부터 선택된 용매를 사용하여 추출물을 수득할 수 있다. 바람직하게는 물 및 메탄올 혼합 용매, 더 바람직하게는 50~100% 메탄올, 더욱 더 바람직하게는 70% 메탄올을 사용하여 추출물을 수득할 수 있다. In addition, the Kakadu plum extract may be an extract extracted by adding an organic solvent to Kakadu plum, and a solvent selected from water including purified water, lower alcohols having 1 to 4 carbon atoms, such as methanol, ethanol, butanol, or a mixture thereof. can be used to obtain an extract. Preferably, an extract can be obtained using a mixed solvent of water and methanol, more preferably 50 to 100% methanol, and still more preferably 70% methanol.
본 발명자들은 문헌에 기재된 방법을 참고하여, 화학식 1로 표시되는 런시나트사이드 화합물을 수득하였다(Zhi-Hong Zhou, Min-Zhuo Liu, Meng-Hua Wang, Wei Qu, Jian-Bo Sun, Jing-Yu, Liang & Fei-Hua Wu (24 February 2015, At: 13:15): A new ellagic acid derivative from Polygonum runcinatum, Natural Product Research: Formerly Natural Product Letters).The present inventors obtained the runcinatside compound represented by Formula 1 with reference to the method described in the literature (Zhi-Hong Zhou, Min-Zhuo Liu, Meng-Hua Wang, Wei Qu, Jian-Bo Sun, Jing-Yu) , Liang & Fei-Hua Wu (24 February 2015, At: 13:15): A new ellagic acid derivative from Polygonum runcinatum, Natural Product Research: Formerly Natural Product Letters).
본 발명의 런시나트사이드 화합물을 유효성분으로 포함하는 조성물은 탈모 방지 및 발모 촉진을 위한 용도로 사용할 수 있다. 따라서, 본 발명의 런시나트사이드 화합물은 탈모 예방 및 발모 촉진용 새로운 소재, 예컨대 약학적 조성물, 화장료 조성물, 식품 조성물로 활용할 수 있다. The composition comprising the runcinatside compound of the present invention as an active ingredient can be used for preventing hair loss and promoting hair growth. Therefore, the runcinatside compound of the present invention can be utilized as a new material for preventing hair loss and promoting hair growth, for example, a pharmaceutical composition, a cosmetic composition, or a food composition.
본 발명의 일 측면에서, 본 발명은 런시나트사이드 화합물 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 탈모 방지 및 발모 촉진용 약학적 조성물을 제공한다. In one aspect of the present invention, the present invention provides a pharmaceutical composition for preventing hair loss and promoting hair growth, comprising the runcinatside compound or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명에 따른 약학적 조성물은 런시나트사이드 화합물 또는 이의 약학적으로 허용가능한 염을 단독으로 함유하거나 또는 하나 이상의 약학적으로 허용되는 담체, 부형제 또는 희석제를 추가로 함유할 수 있다.The pharmaceutical composition according to the present invention may contain the runcinatside compound or a pharmaceutically acceptable salt thereof alone, or may additionally contain one or more pharmaceutically acceptable carriers, excipients or diluents.
상기 약학적으로 허용되는 담체로는 예컨대, 경구 투여용 담체 또는 비경구 투여용 담체를 추가로 포함할 수 있다. 경구 투여용 담체는 락토스, 전분, 셀룰로스 유도체, 마그네슘 스테아레이트, 스테아르산 등을 포함할 수 있다. 또한, 비경구 투여용 담체는 물, 적합한 오일, 식염수, 수성 글루코스 및 글리콜 등을 포함할 수 있으며, 안정화제 및 보존제를 추가로 포함할 수 있다. 적합한 안정화제로는 아황산수소나트륨, 아황산나트륨 또는 아스코르브산과 같은 항산화제가 있다. 적합한 보존제로는 벤즈알코늄 클로라이드, 메틸- 또는 프로필-파라벤 및 클로로부탄올이 있다. 그 밖의 약학적으로 허용되는 담체로는 다음의 문헌에 기재되어 있는 것을 참고로 할 수 있다(Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).The pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. In addition, the carrier for parenteral administration may include water, a suitable oil, saline, aqueous glucose and glycol, and the like, and may further include a stabilizing agent and a preservative. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. As other pharmaceutically acceptable carriers, reference may be made to those described in the following literature (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).
상기에서 "약학적으로 허용되는"이란 생리학적으로 허용되고 인간에게 투여될 때, 통상적으로 위장장애, 현기증과 같은 알레르기 반응 또는 이와 유사한 반응을 일으키지 않는 것을 말한다. As used herein, the term "pharmaceutically acceptable" means that it is physiologically acceptable and does not normally cause allergic reactions such as gastrointestinal disorders, dizziness, or similar reactions when administered to humans.
상기 조성물에 대해 런시나트사이드는 1~5%의 농도 또는 조성물 총 중량에 대해 0.01 내지 70 중량%로 함유될 수 있다. 또한, 본 발명에 따른 런시나트사이드 화합물의 약학적으로 유효한 양은 0.5~100 mg/day/체중kg, 예컨대 0.5~10mg/day/체중kg이다. 그러나, 상기 약학적으로 유효한 양은 탈모 증상의 정도, 환자의 연령, 체중, 건강상태, 성별, 투여 경로 및 치료 기간 등에 따라 적절히 변화될 수 있다. With respect to the composition, runcinatside may be contained in a concentration of 1 to 5% or 0.01 to 70% by weight based on the total weight of the composition. In addition, the pharmaceutically effective amount of the runcinatside compound according to the present invention is 0.5 to 100 mg/day/kg body weight, for example, 0.5 to 10 mg/day/kg body weight. However, the pharmaceutically effective amount may be appropriately changed depending on the degree of hair loss symptoms, the age, weight, health status, sex, administration route, and treatment period of the patient.
또한, 본 발명의 조성물은 포유동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 공지된 방법을 사용하여 제형화될 수 있다. 제형은 분말, 과립, 정제, 에멀젼, 시럽, 에어로졸, 연질 또는 경질 젤라틴 캅셀, 멸균 주사용액, 멸균 분말의 형태일 수 있다.In addition, the compositions of the present invention may be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. Formulations may be in the form of powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, sterile powders.
본 발명에 따른 조성물은 경구, 경피, 피하, 정맥 또는 근육을 포함한 여러경로를 통해 투여될 수 있으며, 활성 성분의 투여량은 투여 경로, 환자의 연령, 성별, 체중 및 환자의 중증도 등의 여러 인자에 따라 적절히 선택될 수 있다. The composition according to the present invention may be administered through several routes including oral, transdermal, subcutaneous, intravenous or intramuscular, and the dosage of the active ingredient depends on several factors such as the route of administration, the patient's age, sex, body weight, and the severity of the patient. may be appropriately selected according to
또한, 본 발명의 탈모 방지 및 발모 촉진용 조성물은 탈모 방지 및 발모 촉진 작용을 손상시키지 않는 한도에서 종래부터 사용되어오던 양모제 또는 육모제를 혼합하여 사용할 수 있다. In addition, the composition for preventing hair loss and promoting hair growth of the present invention can be used by mixing a hair growth agent or a hair growth agent that has been conventionally used as long as it does not impair the hair loss prevention and hair growth promoting action.
또한, 본 발명의 약학 조성물은 개별 제제로 투여되거나 다른 제제와 병용하여 투여될 수 있다. 다른 치료제와 병용하여 투여되는 경우, 본 발명의 조성물과 다른 치료제는 동시에, 개별적으로 또는 순차적으로 투여될 수 있다. 상기 다른 제제는 탈모 방지 및 발모 촉진 효과를 갖는 것으로 이미 알려져 있는 물질일 수 있으며, 여기에는 약물 요법 이외의 외과적 처치, 수술 등이 모두 포함된다. 본 발명의 약학적 조성물이 다른 제제와 병용하여 투여될 경우, 본 발명의 조성물과 다른 제제는 각각 별도의 용기로 분리시켜 제형화되거나, 동일한 용기에서 함께 제형화될 수 있다.In addition, the pharmaceutical composition of the present invention may be administered as an individual agent or in combination with other agents. When administered in combination with other therapeutic agents, the composition of the present invention and the other therapeutic agents may be administered simultaneously, separately, or sequentially. The other agent may be a substance already known to have an effect of preventing hair loss and promoting hair growth, and this includes all surgical treatments other than drug therapy, surgery, and the like. When the pharmaceutical composition of the present invention is administered in combination with another agent, the composition of the present invention and the other agent may be formulated separately in separate containers, or may be formulated together in the same container.
본 발명의 또다른 측면에서, 본 발명은 런시나트사이드 화합물 또는 이의 식품학적으로 허용가능한 염을 유효성분으로 포함하는, 탈모 방지 및 발모 촉진용 식품 조성물을 제공한다. 특히, 본 발명에 따른 런시나트사이드 화합물은 세포에 대한 독성을 유발하지 않고 부작용을 일으키지 않아 안정성이 있어 체내에 안심하고 사용할 수 있으므로 식품 조성물로 사용할 수 있으며, 나아가 모발 증식 효과가 있는 식품, 예컨대, 식품의 주원료, 부원료, 식품 첨가제, 기능성 식품 또는 음료로 용이하게 활용할 수 있다. In another aspect of the present invention, the present invention provides a food composition for preventing hair loss and promoting hair growth, comprising the runcinatside compound or a pharmaceutically acceptable salt thereof as an active ingredient. In particular, the runcinatside compound according to the present invention does not cause toxicity to cells and does not cause side effects, so it has stability and can be used safely in the body, so it can be used as a food composition, and furthermore, a food having a hair growth effect, such as, It can be easily used as a main ingredient, subsidiary ingredient, food additive, functional food or beverage of food.
본 발명에 따른 식품 조성물에서 각 용어는 특별히 언급하지 않는 한 상기 탈모 방지 및 발모 촉진용 약학 조성물에서 상기한 바와 동일한 의미를 갖는다.In the food composition according to the present invention, each term has the same meaning as described above in the pharmaceutical composition for preventing hair loss and promoting hair growth, unless otherwise specified.
본 명세서에서 "식품"이란, 영양소를 한 가지 또는 그 이상 함유하고 있는 천연물 또는 가공품을 의미한다. 바람직하게는, 소정의 가공 공정을 거쳐 직접 먹을 수 있는 상태가 된 것을 의미한다. 여기에는 식품, 식품 첨가제, 기능성 식품 및 음료 등이 포함되지만, 이에 제한되는 것은 아니다.As used herein, "food" means a natural product or processed product containing one or more nutrients. Preferably, it means that it is in a state that can be eaten directly through a predetermined processing process. This includes, but is not limited to, foods, food additives, functional foods and beverages.
본 발명에 따른 탈모 방지 및 발모 촉진용 조성물을 첨가할 수 있는 식품으로는 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 기능성 식품 등이 있다. 추가로, 본 발명에서 식품에는 특수영양식품(예컨대, 조제유류, 영,유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예컨대, 라면류, 국수류 등), 빵류, 건강보조식품, 조미식품(예컨대, 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예컨대, 스낵류), 캔디류, 쵸코렛류, 껌류, 아이스크림류, 유가공품(예컨대, 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(각종 김치류, 장아찌 등), 음료(예컨대, 과실 음료, 채소류 음료, 두유류, 발효음료류 등), 천연조미료(예컨대, 라면 스프 등)을 포함하지만, 이에 한정되지 않는다. 상기 식품, 음료 또는 식품첨가제는 통상의 제조방법으로 제조될 수 있다. Foods to which the composition for preventing hair loss and promoting hair growth according to the present invention can be added include, for example, various foods, beverages, gums, tea, vitamin complexes, functional foods, and the like. In addition, in the present invention, food includes special nutritional foods (eg, formula milk, infant food, etc.), processed meat products, fish meat products, tofu, jelly, noodles (eg, ramen, noodles, etc.), breads, health supplements, seasonings Food (eg, soy sauce, soybean paste, red pepper paste, mixed soy sauce, etc.), sauces, confectionery (eg, snacks), candy, chocolate, gum, ice cream, dairy products (eg, fermented milk, cheese, etc.), other processed foods, kimchi, Pickled foods (various kimchi, pickles, etc.), beverages (eg, fruit beverages, vegetable beverages, soy milk, fermented beverages, etc.), and natural seasonings (eg, ramen soup, etc.) are not limited thereto. The food, beverage or food additive may be prepared by a conventional manufacturing method.
상기 식품은 건강기능성 식품일 수 있다. 용어 "건강기능성 식품"이란, 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상, 환 등의 형태로 제조 및 가공한 식품을 의미한다. 여기서 "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻는 것을 의미한다.The food may be a health functional food. The term "health functional food" refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. using raw materials or ingredients useful in the human body. Herein, the term "functionality" refers to obtaining useful effects for health purposes, such as regulating nutrients or physiological actions with respect to the structure and function of the human body.
본 발명에 따른 식품 조성물은 당업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조 시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나므로, 본 발명의 식품 조성물은 림프부종의 치료 효과를 증진 또는 개선시키기 위한 보조제로 섭취가 가능하다. The food composition according to the present invention can be prepared by a method commonly used in the art, and during the preparation, it can be prepared by adding raw materials and components commonly added in the art. In addition, unlike general drugs, there is no side effect that may occur when taking the drug for a long time using food as a raw material, and since it is excellent in portability, the food composition of the present invention is used to enhance or improve the therapeutic effect of lymphedema. It can be taken as a supplement for
본 발명에 따른 식품 조성물에 유효성분으로서 포함되는 화합물 또는 이의 염의 양은 구체적인 사용 목적에 따라 적합하게 결정될 수 있다. 본 발명의 탈모 방지 및 발모 촉진용 조성물을 함유하는 식품에 있어서, 상기 본 발명에 따른 조성물의 양은 전체 식품 중량의 0.001 중량% 내지 90 중량%로 포함할 수 있으며, 바람직하게는 0.1 중량% 내지 40 중량%로 포함할 수 있다. 음료의 경우, 100ml를 기준으로 0.001g 내지 2g, 바람직하게는 0.01g 내지 0.1g의 비율로 포함할 수 있다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하로도 사용될 수 있다. 상기 식품 조성물을 제조하는 과정에서 식품 조성물에 첨가되는 본 발명에 따른 화합물 또는 이의 염은 필요에 따라 그 함량을 적절히 가감할 수 있다.The amount of the compound or salt thereof included as an active ingredient in the food composition according to the present invention may be suitably determined depending on the specific purpose of use. In the food containing the composition for preventing hair loss and promoting hair growth of the present invention, the amount of the composition according to the present invention may be included in an amount of 0.001 wt% to 90 wt% of the total food weight, preferably 0.1 wt% to 40 wt% It may be included in weight %. In the case of a beverage, it may be included in a ratio of 0.001 g to 2 g, preferably 0.01 g to 0.1 g, based on 100 ml. However, in the case of long-term intake for health and hygiene purposes or for health control purposes, the above amount may be used below the above range. The compound according to the present invention or a salt thereof added to the food composition in the process of preparing the food composition may be appropriately increased or decreased in its content as needed.
본 발명의 식품 조성물은 효능 증진을 위해 상기 화합물 또는 이의 염 외에 추가 성분을 더 포함할 수 있다. The food composition of the present invention may further include additional ingredients in addition to the above compound or a salt thereof to enhance efficacy.
상기 식품 조성물은 환제, 정제, 과립, 분말, 캡슐, 액상의 용액으로 이루어진 군으로부터 선택된 어느 하나의 제형일 수 있다.The food composition may be in any one formulation selected from the group consisting of pills, tablets, granules, powders, capsules, and liquid solutions.
또한, 상기 식품의 종류는 특별한 제한되지 않는다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 식품을 모두 포함한다.In addition, the type of the food is not particularly limited. Examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks, There are alcoholic beverages, vitamin complexes, and the like, and includes all foods in a conventional sense.
본 발명의 식품 조성물은 통상의 식품과 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 수크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. The food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, like conventional food. The natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as taumatine and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like can be used.
본 발명의 식품 조성물이 음료 조성물일 경우 필수 성분으로서 상기 화합물 또는 이의 염을 지시된 비율로 함유하는 외에는 액체 성분에 특별한 제한점은 없으며, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.When the food composition of the present invention is a beverage composition, there is no particular limitation on the liquid component except for containing the compound or its salt in the indicated ratio as an essential component, and as in a conventional beverage, various flavoring agents or natural carbohydrates are added as additional components. can be contained as
본 발명의 또다른 측면에서, 본 발명은 런시나트사이드 또는 이의 화장품학적으로 허용가능한 염을 유효성분으로 포함하는, 탈모 방지 또는 발모 촉진용 화장품 조성물을 제공한다.In another aspect of the present invention, the present invention provides a cosmetic composition for preventing hair loss or promoting hair growth, comprising runcinatside or a cosmetically acceptable salt thereof as an active ingredient.
본 발명에 따른 화장품 조성물에서 각 용어는 특별히 언급하지 않는 한 상기 약학 조성물 또는 식품 조성물에서 전술한 바와 동일한 의미를 갖는다.In the cosmetic composition according to the present invention, each term has the same meaning as described above in the pharmaceutical composition or food composition unless otherwise specified.
본 발명의 화장품 조성물은 단독으로 적용할 수 있을 뿐만 아니라, 본 발명의 약학 조성물 및/또는 식품 조성물과 동시에 적용 가능하며, 탈모 방지 또는 발모 촉진 효과를 증진시킬 수 있다.The cosmetic composition of the present invention can be applied alone, and can be applied simultaneously with the pharmaceutical composition and/or food composition of the present invention, and can enhance the effect of preventing hair loss or promoting hair growth.
본 발명에 따른 화장품 조성물은 당업계에서 통상적으로 사용되는 방법에 의하여 제조가능하며, 상기 제조 시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다.The cosmetic composition according to the present invention can be prepared by a method commonly used in the art, and at the time of manufacture, it can be prepared by adding raw materials and components commonly added in the art.
본 발명에 따른 화장품 조성물에 유효성분으로 포함되는 화합물 또는 이의 염의 함량은 사용 목적(예방, 개선 또는 치료적 처치), 사용 기간, 제형의 종류, 투여 경로, 대상체의 상태 등 다양한 요인을 고려하여 적합하게 결정될 수 있다. 예를 들어, 화합물 또는 이의 염의 함량은 화장품 조성물 전체 중량을 기준으로 0.001 내지 10 중량%, 예컨대 0.01 내지 5 중량%일 수 있다. 본 발명에 따른 화장품 조성물은 통상적으로 알려진 제조방법을 이용하여, 일반적인 유화 제형 및 가용화 제형 등의 형태로 제조될 수 있다. 이때, 본 발명의 화장품 조성물은 패치류, 연고류, 피부접착용 겔류, 크림류, 팩류, 화장수류, 에센스류, 스프레이류, 마스크류, 파운데이션류, 메이크업베이스류, 세정제류, 수(W)형, 유(O)형, 실리콘(S)형, 수중유(O/W)형, 유중수(W/O)형, 실리콘중수(W/S)형, 수중실리콘(S/W)형, 고체상, 액상 등의 다양한 제형으로 제조될 수 있다.The content of the compound or salt thereof included as an active ingredient in the cosmetic composition according to the present invention is suitable in consideration of various factors such as the purpose of use (prevention, improvement or therapeutic treatment), the period of use, the type of formulation, the route of administration, the condition of the subject, etc. can be decided For example, the content of the compound or salt thereof may be 0.001 to 10% by weight, such as 0.01 to 5% by weight, based on the total weight of the cosmetic composition. The cosmetic composition according to the present invention may be prepared in the form of a general emulsified formulation and a solubilized formulation using a conventionally known manufacturing method. At this time, the cosmetic composition of the present invention includes patches, ointments, gels for skin adhesion, creams, packs, lotions, essences, sprays, masks, foundations, makeup bases, detergents, water (W) type, Oil (O) type, silicone (S) type, oil-in-water (O/W) type, water-in-oil (W/O) type, water-in-silicone (W/S) type, silicone in water (S/W) type, solid, It can be prepared in various formulations such as liquid.
본 발명에 따른 화장품 조성물은 효능 증진을 위해 상기 유효성분 외에 추가 성분을 더 포함할 수 있다. 예를 들어, 상기 추가 성분은 본 발명에 따른 화합물 또는 이의 염의 효능을 상쇄시키거나 감소시키지 않는다면 제한이 없다. 선택적으로, 화장품 분야에서 통상적으로 사용되는 보조제, 담체 등을 추가로 포함할 수 있다. 선택적으로, 화장품 기능을 부가하거나 증대시키기 위하여 전형적으로 사용되는 성분들이 또한 추가될 수 있다. 예를 들면, 안정화제, 유화제, 점증제, 보습제, 액정 막강화제, pH 조절제, 항균제, 수용성 고분자, 피막제, 금속 이온 봉쇄제, 아미노산, 유기 아민, 고분자 에멀션, pH 조정제, 피부 영양제, 산화 방지제, 산화 방지조제, 방부제, 향료 등에서 선택되는 하나 이상의 수성 첨가제; 및 유지류, 왁스류, 탄화 수소유, 고급 지방산유, 고급 알콜, 합성 에스테르유 및 실리콘유 등에서 선택되는 하나 이상의 유성 첨가제 등이 추가될 수 있다.The cosmetic composition according to the present invention may further include additional ingredients in addition to the active ingredients to enhance efficacy. For example, said additional ingredients are not limited as long as they do not counteract or reduce the efficacy of the compounds according to the invention or salts thereof. Optionally, it may further include adjuvants, carriers, etc. commonly used in the cosmetic field. Optionally, ingredients typically used to add or enhance cosmetic functions may also be added. For example, stabilizers, emulsifiers, thickeners, humectants, liquid crystal film strengthening agents, pH regulators, antibacterial agents, water-soluble polymers, film agents, sequestering agents, amino acids, organic amines, polymer emulsions, pH regulators, skin nutrients, antioxidants, one or more aqueous additives selected from antioxidants, preservatives, fragrances, and the like; and at least one oily additive selected from oils and fats, waxes, hydrocarbon oil, higher fatty acid oil, higher alcohol, synthetic ester oil, silicone oil, and the like may be added.
본 발명의 조성물에 유효성분으로 포함되는 런시나트사이드 또는 이의 염은 탈모 방지 및/또는 발모 촉진 효과가 있다. 또한, 상기 런시나트사이드는 모낭 모유두 세포 및/또는 모발 외측 모근초 세포의 생존율을 증가시킬 수 있으며, 모발 길이를 신장시키는 활성을 갖는다. 따라서, 부작용은 없으면서 탈모 방지 및/또는 발모 촉진 효과는 우수한 약학적 조성물, 식품 조성물 또는 화장료 조성물이 제공된다.Runcinatside or a salt thereof included as an active ingredient in the composition of the present invention has an effect of preventing hair loss and/or promoting hair growth. In addition, the runcinatside can increase the survival rate of hair follicle dermal papilla cells and/or outer hair root sheath cells, and has an activity of extending hair length. Accordingly, there is provided a pharmaceutical composition, a food composition or a cosmetic composition that has no side effects while preventing hair loss and/or promoting hair growth.
도 1은 C57BL/6 마우스 모델에 대한, 런시나트사이드 1%, 3% 또는 5% 처리군, 정상대조군과 용매대조군의 음성 대조군, 미녹시딜 3% 처리 양성대조군의 육모 촉진 효과를 1일, 6일, 12일, 16일, 21일의 경과로 나타낸 것이다.
도 2는 C57BL/6 마우스 모델에 대한, 런시나트사이드 1%, 3% 또는 5% 처리군, 정상대조군과 용매대조군의 음성 대조군, 미녹시딜 3% 처리 양성대조군의 Alkaline phosphatase(ALP) 활성을 1일, 6일, 12일, 16일, 21일의 경과로 나타낸 것이다.
도 3은 C57BL/6 마우스 모델에 대한, 런시나트사이드 1%, 3% 또는 5% 처리군, 정상대조군과 용매대조군의 음성 대조군, 미녹시딜 3% 처리 양성대조군의 γ-GT(γ-Glutamyl transpeptidase)의 활성을 1일, 6일, 12일, 16일, 21일의 경과로 나타낸 것이다.1 is for the C57BL/6 mouse model, 1%, 3% or 5% of runcinatside treatment group, the negative control group of the normal control group and the solvent control group, the hair growth promoting effect of the minoxidil 3% treatment
2 is Alkaline phosphatase (ALP) activity of 1%, 3% or 5% treatment group, normal control group and solvent control group, negative control group, minoxidil 3% treatment group positive control group for C57BL/6
Figure 3 is for the C57BL/6 mouse model, 1%, 3% or 5% of runcinatside treatment group, a negative control group of a normal control group and a solvent control group, a positive control group treated with minoxidil 3% γ-GT (γ-Glutamyl transpeptidase) The activity of 1 day, 6 days, 12 days, 16 days, is shown as the lapse of 21 days.
이하 본 발명을 실시예에 의해 보다 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것은 아니다. 또한, 당해 기술분야에서 통상의 지식을 가진 자라면 본 발명의 취지를 해하지 않는 범위 내에서 본 발명에 대해 다양한 변형 및 수정을 가할 수 있을 것이다. 본 명세서에서 특별히 정의되지 않은 용어들에 대해서는 본 발명이 속하는 기술 분야에서 통상적으로 사용되는 의미를 갖는 것으로 이해되어야 할 것이다.Hereinafter, the present invention will be described in more detail by way of Examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited by these examples. In addition, those of ordinary skill in the art will be able to make various changes and modifications to the present invention within the scope that does not impair the spirit of the present invention. It should be understood that terms not specifically defined in this specification have meanings commonly used in the technical field to which the present invention pertains.
실시예 1Example 1
시료의 준비Sample preparation
카카두플럼은 멕시코 원산 재료를 아마존 웹사이트를 통해 2020년 1월에 구입하였다. 표본(Skedrm20200103)을 대한민국 SKEDERM 코스메틱 R&D 센터 내 원재료실에 보관하였다. 실리카 겔(200-300 mesh)은 Merck Co. Ltd로부터 구입하였다. 3% 미녹시딜(Sigma-Aldrich, St. Louis, MO, USA) 및 에탄올(Sigma-Aldrich, St. Louis, MO, USA)을 참조 시약으로 사용하기 위하여 구입하였다. NMR 스펙트럼은 Varian Inova-400 FT-NMR spectrometer(CA, USA)에 의해 측정하였다(내부 표준으로서 TMS, δ in ppm, J in Hz). 고분해능 전기 분무 이온화 질량 분석(HR-ESI-MS)은 Bruker APEXII mass spectrometer에 의해 측정하였다(m/z). EI-MS는 VG ZABHS mass spectrometer(70 eV)에 의해 측정하였다.Kakadu Plum purchased ingredients from Mexico in January 2020 through the Amazon website. The specimen (Skedrm20200103) was stored in the raw material room in SKEDERM Cosmetics R&D Center in Korea. Silica gel (200-300 mesh) is manufactured by Merck Co., Ltd. Ltd. 3% minoxidil (Sigma-Aldrich, St. Louis, MO, USA) and ethanol (Sigma-Aldrich, St. Louis, MO, USA) were purchased for use as reference reagents. NMR spectra were measured by a Varian Inova-400 FT-NMR spectrometer (CA, USA) (TMS as internal standard, δ in ppm, J in Hz). High-resolution electrospray ionization mass spectrometry (HR-ESI-MS) was measured by a Bruker APEXII mass spectrometer (m/z). EI-MS was measured by a VG ZABHS mass spectrometer (70 eV).
런시나트사이드 화합물의 분리Isolation of Runcinatside Compounds
건조된 카카두플럼을 에탄올로 3회 환류추출하였다. 주요 활성 성분을 분리하기 위해 추출여과액은 진공하에 700mL로 농축시켰다. 그 후, 추출은 동일하게 연속적으로 CHCl3, EtOAc 및 n-BuOH의 용매를 이용하여 계통 분획하였다. CHCl3 추출물(50g)을 컬럼에 처리하여, 용매구배 CH2Cl2-MeOH(100:1 내지 1:1)를 사용하여 실리카 겔상에서 크로마토그래피를 통해 5개의 분획(Fr. 1 - Fr. 5)으로 나누었다. 분획 2(Fr. 2)는 추가로 세파덱스 LH-20상에서 크로마토그래피(MeOH)에 적용하여 런시나트사이드를 0.64% 수득하였다. 물질 구조를 규명하기 위하여 proton-NMR, carbon-NMR 및 COSY, DEPT, HMBC, HMQC를 수행하여 본 발명의 런시나트사이드 구조를 확인하였다.The dried kakadu plum was extracted under reflux three times with ethanol. To isolate the main active ingredient, the extract filtrate was concentrated under vacuum to 700 mL. Thereafter, the extraction was systematically fractionated using a solvent of CHCl 3 , EtOAc and n-BuOH in the same succession. The CHCl 3 extract (50 g) was subjected to column chromatography in 5 fractions (Fr. 1 - Fr. 5) on silica gel using a solvent gradient CH 2 Cl 2 -MeOH (100:1 to 1:1). ) divided by Fraction 2 (Fr. 2) was further subjected to chromatography (MeOH) on Sephadex LH-20 to obtain 0.64% of runcinatside. To elucidate the material structure, proton-NMR, carbon-NMR, and COSY, DEPT, HMBC, and HMQC were performed to confirm the runcinatside structure of the present invention.
1H NMR (300 MHz, DMSO-d6) d: 7.54 (1H, s, H-5), 7.81 (1H, s, H-50), 5.29 (1H, d, J ¼ 6.0 Hz, H-100), 3.41 (1H, brs, H-200), 3.41 (1H, brs, H-300), 3.41 (1H, brs, H-400), 3.81 (1H, d, J ¼ 4.1 Hz, H-500), 4.47 (1H, d, J ¼ 10.2 Hz, H-6a00), 4.28 (1H, dd, J ¼ 12.0, 4.8 Hz, H-6b00), 6.87 (2H, s, H-2000,6000), 4.06 (6H, s, 3,30-OCH3); 1H NMR (300 MHz, DMSO-d6) d: 7.54 (1H, s, H-5), 7.81 (1H, s, H-50), 5.29 (1H, d, J ¼ 6.0 Hz, H-100), 3.41 (1H, brs, H-200), 3.41 (1H, brs, H-300), 3.41 (1H, brs, H-400), 3.81 (1H, d, J ¼ 4.1 Hz, H-500), 4.47 (1H, d, J ¼ 10.2 Hz, H-6a00), 4.28 (1H, dd, J ¼ 12.0, 4.8 Hz, H-6b00), 6.87 (2H, s, H-2000,6000), 4.06 (6H, s, 3,30-OCH 3 );
13C NMR (75 MHz, DMSO-d6) d: 112.0 (C-1), 141.7 (C-2), 140.2 (C-3), 152.8 (C-4), 111.6 (C-5), 111.1 (C-6), 158.3 (C-7), 112.7 (C-10), 141.0 (C-20), 141.9 (C-30), 151.2 (C-40), 112.1 (C-50), 114.3 (C-60), 158.4 (C-70), 101.2 (C-100), 73.3 (C-200), 76.1 (C-300), 69.5 (C-400), 73.9 (C-500), 63.0 (C-600), 119.2 (C-1000), 108.6 (C-2000,6000), 145.3 (C-3000,5000), 138.4 (C-4000), 165.7 (C-7000), 61.0 (3-OCH3), 61.6 (30-OCH3).13 C NMR (75 MHz, DMSO-d6) d: 112.0 (C-1), 141.7 (C-2), 140.2 (C-3), 152.8 (C-4), 111.6 (C-5), 111.1 (C -6), 158.3 (C-7), 112.7 (C-10), 141.0 (C-20), 141.9 (C-30), 151.2 (C-40), 112.1 (C-50), 114.3 (C- 60), 158.4 (C-70), 101.2 (C-100), 73.3 (C-200), 76.1 (C-300), 69.5 (C-400), 73.9 (C-500), 63.0 (C-600) ), 119.2 (C-1000), 108.6 (C-2000,6000), 145.3 (C-3000,5000), 138.4 (C-4000), 165.7 (C-7000), 61.0 (3-OCH 3 ), 61.6 (30-OCH 3 ).
실험예 1Experimental Example 1
런시나트사이드 화합물의 생물학적 기능 평가Evaluation of Biological Functions of Runcinatside Compounds
런시나트사이드 화합물의 모발 증식 활성을 확인하기 위하여 동물실험을 수행하였다. 생후 5주된 수컷 C57BL6 마우스를 1주 동안 동물사육실 환경에 적응시킨 후, 실험에 사용하였다. C57BL6 마우스는 체모가 검정색이고, 자연적 탈모가 일어나는 특징을 가진다.An animal experiment was performed to confirm the hair growth activity of the runcinatside compound. Five-week-old male C57BL6 mice were acclimatized to the animal room environment for 1 week, and then used for experiments. C57BL6 mice have black body hair and natural hair loss.
동물사육실의 조건으로서, 온도 23±3℃, 상대습도 50±10%, 12시간 간격으로 밤과 낮을 유지하였다. 실험동물은 격리용 사육상자(ThreeShine)에서 사육하였으며, 실험동물용 사료를 자유롭게 급여하였다. As the conditions of the animal breeding room, the temperature was 23±3℃, the relative humidity was 50±10%, and the night and day were maintained at 12 hour intervals. Experimental animals were bred in isolation breeding boxes (ThreeShine), and feed for laboratory animals was freely fed.
실험군은 총 6개의 군으로 나누었으며, 즉 정상대조군(Saline), 용매대조군(50% EtOH), 양성대조군(3% 미녹시딜), 실험군(1%, 3%, 5% 런시나트사이드)로 나누었다. 각 군당 5마리씩 총 30마리를 실험하였다.The experimental group was divided into a total of 6 groups, namely, a normal control group (Saline), a solvent control group (50% EtOH), a positive control group (3% minoxidil), and an experimental group (1%, 3%, 5% runcinatside). A total of 30 animals were tested, 5 in each group.
등쪽 피부가 핑크색을 보이는 휴지기 체모의 6주령을 사용하였으며, 제모는 Electrical Animal Clipper와 면도기를 이용하여 조심스럽게 마우스 등판의 털을 깎아 내어 제거하였다. 그 후, 제모된 부위에 붓을 이용하여 150㎕의 시료를 각 군별로 도포하였다. A 6-week-old with resting body hair with pink dorsal skin was used, and the hair was removed by carefully shaving off the back of the mouse using an Electrical Animal Clipper and a razor. Thereafter, 150 μl of a sample was applied to each group by using a brush on the hair-removed area.
시료의 처리는 매일 오전 10시에 1회씩 3주 동안 실시하였다. 시료로서 1%, 3%, 5% 런시나트사이드와 3% 미녹시딜을 실험 시작 후 실험군과 양성대조군의 피부(제모 부위)에 매일 도포하였으며, 정상대조군에는 saline을 도포하였으며, 용매대조군에는 50% EtOH을 도포하였다. 여기서, 3% 미녹시딜이라고 하면, 외용액 약 3.3 mL 중 미녹시딜 100 mg이 함유된 것을 의미한다.Samples were treated once every day at 10 am for 3 weeks. As samples, 1%, 3%, 5% runcinatside and 3% minoxidil were applied daily to the skin (hair removal area) of the experimental group and the positive control group after the start of the experiment, saline was applied to the normal control group, and 50% EtOH to the solvent control group. was applied. Here, 3% minoxidil means that 100 mg of minoxidil is contained in about 3.3 mL of an external solution.
실험 시작 후 1일, 6일, 12일, 16일 그리고 21일에 털이 자라는 상태를 육안으로 관찰하였으며, 모든 군에서 실험 12일 이후부터 털이 자라는 것이 뚜렷하게 관찰되었다. 21일째 용매대조군의 털이 자란 부위는 전체 면적 중 28.3±8.4%로 나타났으며, 이에 비해 1% 런시나트사이드 처리 실험군은 56.9±8.4%로, 3% 런시나트사이드 처리 실험군은 66.5±6.3%로, 5% 런시나트사이드군 처리 실험군은 61.4±7.1%로 관찰되어 약 2배 이상 빠른 모발의 성장 효과가 나타났다. 양성대조군(3% 미녹시딜)과 실험군(1%, 3%, 5% 런시나트사이드)은 비슷한 털의 성장 효과를 보였으며, 특히 실험군에서는 양성대조군에 비해 개체별 털의 성장 차이가 적고 보다 균일하게 나타났다(도 1).Hair growth was observed with the naked eye on the 1st, 6th, 12th, 16th, and 21st days after the start of the experiment, and hair growth was clearly observed from the 12th day onwards in all groups. On the 21st day, the hair growth area of the solvent control group was 28.3±8.4% of the total area, compared to 56.9±8.4% in the 1% runcinatside treatment group and 66.5±6.3% in the 3% runcinatside treatment group. , 61.4±7.1% of the 5% runcinatside treatment group was observed, indicating a hair growth effect more than twice as fast. The positive control group (3% minoxidil) and the experimental group (1%, 3%, 5% runcinatside) showed similar hair growth effects. appeared (Fig. 1).
실험예 2Experimental Example 2
런시나트사이드 화합물의 피부조직의 효소 활성도Enzyme Activity of Skin Tissue of Runcinatside Compound
본 실험예에서는 런시나트사이드 화합물이 피부조직의 효소 활성도와 밀접한 연관이 있는지를 조사하였다. 이를 위하여 알카라인 포스파타아제(Alkaline phosphatase; ALP) 실험을 시행하였다.In this experimental example, it was investigated whether the runcinatside compound is closely related to the enzyme activity of the skin tissue. For this purpose, an alkaline phosphatase (ALP) experiment was performed.
ALP는 주로 혈관신생에 관여하며, 진피유두에 밀집되어 있는 모세혈관으로 영양을 공급함으로써 발모 작용을 원활하게 해 주는 것으로 알려져 있다. 따라서 ALP 측정을 통해 발모 작용을 추측할 수 있는 것으로 보고되고 있다. non-growth 부위에 비해 re-growth 부위에서 알카라인 포스파타아제 활성이 현저히 증가함이 보고된다(박영옥, 김영철, Chamaecyparis Obtusa Oil이 모발성장관련 효소 활성에 미치는 영향, 한국미용학회지, 14(2): p.355-364, 2008). ALP is mainly involved in angiogenesis and is known to facilitate hair growth by supplying nutrients to the capillaries concentrated in the dermal papilla. Therefore, it is reported that the hair growth action can be inferred through ALP measurement. It is reported that alkaline phosphatase activity significantly increased in the re-growth site compared to the non-growth site (Young-Ok Park, Young-Chul Kim, Effect of Chamaecyparis Obtusa Oil on the activity of enzymes related to hair growth, Journal of the Korean Society of Aesthetics, 14(2): p.355-364, 2008).
앞서 실험예 1과 동일한 방식으로 시료를 도포한 마우스에서 1일, 6일, 12일, 16일, 21일에 피부조직을 적출하여 빙냉하에서 미세 절편으로 만들고, 그 중 일정량을 칭량하였다. 그 후, 4배량의 0.1M 인산완충용액(pH 7.4)을 가하고, 마쇄기(BioHomogenizer)를 이용하여 20%(w/v) 균질액을 만들었다. 이 균질액을 12,000rpm에서 4℃에서 30분 동안 원심분리하여, 상층액에서 PMF(post-mitochondrial fraction)을 분리하였다. ρ-nitrophenolphosphate(PNPP)를 기질로 하여 37℃에서 30분 동안 반응시킨 후, 유리된 ρ-nitrophenol에 alkali를 가하여 비색 정량하는 Bessey-Lowry-Brock 방법을 적용하였다. 활성도 단위는 단백질 1mg 당 Bessey-Lowry unit로 하였으며, 단백질의 정량은 Lowry 등의 방법(Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ, Protein measurementwith the Folin phenolreagent, J. Biol.Chem., 193:p. 265-27)에 준하여 bovine albumin을 표준품으로 하여 측정하였다. Skin tissue was extracted from the mice coated with the sample in the same manner as in Experimental Example 1 on
피부조직을 이용한 ALP 활성도 측정결과는 실험 6일 이전에는 모든 군에서 유의한 차이가 없었으나, 시간이 경과함에 따라 그 차이는 현저하게 증가하였다. 12일경에는 양성대조군인 3% 미녹시딜 처리군이 정상대조군과 용매대조군에 비해 유의하게 가장 높은 활성을 나타냈다(p<0.05). 또한 1%, 3%, 5% 런시나트사이드 처리군도 3% 미녹시딜 처리군과 유사한 정도로 높은 활성을 나타냈다(p<0.05). There was no significant difference in the results of ALP activity measurement using skin tissue in all groups before the 6th day of the experiment, but the difference increased remarkably as time passed. On day 12, the positive control group treated with 3% minoxidil showed significantly the highest activity compared to the normal control group and the solvent control group (p<0.05). In addition, 1%, 3%, 5% runcinatside treatment group showed a high activity similar to that of the 3% minoxidil treatment group (p<0.05).
모발 생장기가 일어나는 시기인 8일에서 11일 사이에는 효소 활성이 1%, 3%, 5% 런시나트사이드 처리군에서도 3% 미녹시딜 처리군과 비슷한 양상으로 증가하였으며, 5% 런시나트사이드 처리군에서 가장 높은 증가를 보였다. 16일 이후에도 1%, 3%, 5% 런시나트사이드 처리군과 3% 미녹시딜 처리군은 정상대조군과 용매대조군에 비해 효소 활성이 유의하게 높게 나타났다(p<0.01)(도 2). Between the 8th and 11th days of the hair growth phase, the enzyme activity was increased in the 1%, 3%, and 5% runcinatside treatment groups in a similar manner to the 3% minoxidil treatment group, and in the 5% runcinatside treatment group, showed the highest increase. Even after 16 days, the 1%, 3%, 5% runcinatside treatment group and the 3% minoxidil treatment group showed significantly higher enzyme activity than the normal control group and the solvent control group (p<0.01) ( FIG. 2 ).
실험예 3Experimental Example 3
γ-GT(γ-glutamyl transpeptidase)의 활성 측정Measurement of the activity of γ-GT (γ-glutamyl transpeptidase)
런시나트사이드 화합물에 대해 γ-GT(γ-glutamyl transpeptidase) 활성 실험을 시행하였다. 구체적으로, γ-GT(γ-glutamyl transpeptidase)를 기질로 하여 생성된 5-aminosalicylic Acid를 다시 ρ-xyleno와 Sodium Metaperiodate로 반응시켜 생성된 Kenoid 색소를 635nm에서 측정하는 kit 시약에 의하여 측정하였다. 활성도 단위는 단백질 1mg당 unit로 표시하였다.γ-GT (γ-glutamyl transpeptidase) activity experiment was performed on the runcinatside compound. Specifically, 5-aminosalicylic acid produced by using γ-glutamyl transpeptidase (γ-GT) as a substrate was reacted with ρ-xyleno and sodium metaperiodate again, and the kenoid pigment produced was measured by a kit reagent measuring at 635 nm. Activity units were expressed as units per 1 mg of protein.
상기 γ-GT는 생체 내 산화적 스트레스와 글루타치온(glutathione) 대사, 및 세포막을 통한 아미노산 펩타이드의 흡수 및 분비에 관여하는 효소이며, 글루타메이트,시스테인, 글리신으로 구성된 글루타치온의 체내 대사에 관여한다. 따라서, 세포내 모발의 케라틴화에 주성분인 시스테인을 공급하는데, 발모 주기에서 생장기(anagen)가 유도될 때 γ-GT의 더 많은 발현이 나타난다. 따라서, γ-GT는 발모의 중요한 표지 성분 중 하나로 제시되었다(Hanada,M. and Suzuki,K., Evaluation of biochemical indices as a hair cycle marker in C3H mice, Exp.Anim. 45:p.251,1996).The γ-GT is an enzyme involved in oxidative stress in vivo, glutathione metabolism, and absorption and secretion of amino acid peptides through cell membranes, and is involved in the body metabolism of glutathione composed of glutamate, cysteine, and glycine. Therefore, it supplies cysteine, which is a main component for keratinization of intracellular hair, and more expression of γ-GT appears when anagen is induced in the hair growth cycle. Therefore, γ-GT has been suggested as one of the important markers for hair growth (Hanada, M. and Suzuki, K., Evaluation of biochemical indices as a hair cycle marker in C3H mice, Exp.Anim. 45:p.251,1996). ).
앞서 실험예 1과 동일한 방식으로 시료를 도포한 마우스에서 1일, 6일, 12일, 16일, 21일에서의 γ-GT 활성을 피부조직을 이용하여 측정하였다. 그 결과, 실험 초기에는 양성대조군이 가장 높은 효소 활성을 나타냈으며(p<0.05), 피부색이 핑크색에서 청색으로 변하는 성장기인 8일에서 12일경에는 1%, 3%, 5% 런시나트사이드 처리군이 3% 미녹시딜 처리군과 유사한 값을 나타내었다(p<0.05). 특히, 16일이 경과하면서 5% 런시나트사이드 처리군이 3% 미녹시딜 처리군보다 더 유의하게 높은 활성을 보였다(p<0.001)(도 3). In mice coated with the sample in the same manner as in Experimental Example 1 above, γ-GT activity at 1 day, 6 days, 12 days, 16 days, and 21 days was measured using skin tissue. As a result, the positive control group showed the highest enzyme activity at the beginning of the experiment (p<0.05), and the 1%, 3%, and 5% runcinatside treatment groups on the 8th to 12th days of the growth period when the skin color changes from pink to blue It showed a value similar to the 3% minoxidil treatment group (p<0.05). In particular, after 16 days, the 5% runcinatside treatment group showed significantly higher activity than the 3% minoxidil treatment group (p<0.001) ( FIG. 3 ).
이상과 같이, 본 발명자들은 놀랍게도 런시나트사이드 화합물이 우수한 육모 성장 효과를 보였으며, 모발성장 관련지표인 ALP 및 γ-GT 효소 활성도 현저히 증가하였다. 이에 따라, 런시나트사이드는 두피 개선 및 탈모 방지용 조성물로서의 유용성이 입증되었다.As described above, the present inventors surprisingly showed an excellent hair growth effect of the runcinatside compound, and ALP and γ-GT enzyme activity, which are indicators of hair growth, also significantly increased. Accordingly, runcinatside has proven useful as a composition for improving scalp and preventing hair loss.
위에서 본 발명에 대하여 그 바람직한 실험방법들을 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 실험형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시방법들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특허청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.The preferred experimental methods have been reviewed for the present invention above. Those of ordinary skill in the art to which the present invention pertains will understand that the present invention can be implemented in a modified experimental form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments are to be considered in an illustrative rather than a restrictive sense. The scope of the present invention is indicated in the claims rather than the foregoing description, and all differences within the scope equivalent thereto should be construed as being included in the present invention.
Claims (8)
[화학식 1]
.A pharmaceutical composition for preventing hair loss or promoting hair growth, comprising runcinatside represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient:
[Formula 1]
.
상기 런시나트사이드는 카카두플럼(Terminalia ferdinandiana)으로부터 유래된 것을 특징으로 하는 약학적 조성물.According to claim 1,
The runcinat side is a pharmaceutical composition, characterized in that derived from Kakadu plum (Terminalia ferdinandiana).
상기 약학적 조성물은 피부 외용제로서 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 및 카타플라스마제로 이루어진 군에서 선택되는 제형인 것을 특징으로 하는 약학적 조성물.According to claim 1,
The pharmaceutical composition is a pharmaceutical composition, characterized in that it is a formulation selected from the group consisting of creams, gels, patches, sprays, ointments, warning agents, lotions, liniment agents, pasta agents and cataplasma agents as external preparations for the skin.
[화학식 1]
.A food composition for preventing hair loss and promoting hair growth, comprising runcinatside represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient:
[Formula 1]
.
상기 런시나트사이드는 카카두플럼(Terminalia ferdinandiana)으로부터 유래된 것을 특징으로 하는 식품 조성물.5. The method of claim 4,
The runcinat side is Kakadu plum ( Terminalia ferdinandiana ) Food composition, characterized in that derived from.
[화학식 1]
.A cosmetic composition for preventing hair loss and promoting hair growth, comprising runcinatside represented by the following Chemical Formula 1 or a cosmetically acceptable salt thereof as an active ingredient:
[Formula 1]
.
상기 런시나트사이드는 카카두플럼(Terminalia ferdinandiana)으로부터 유래된 것을 특징으로 하는 화장료 조성물.7. The method of claim 6,
The runcinat side is a cosmetic composition, characterized in that derived from Kakadu plum (Terminalia ferdinandiana).
상기 화장료 조성물은 헤어토닉, 모발 영양화장수, 스칼프트리트먼트, 헤어트리트먼트, 헤어린스, 헤어샴푸 및 헤어로션으로 이루어진 군으로부터 선택되는 제형인 것을 특징으로 하는 화장료 조성물.7. The method of claim 6,
The cosmetic composition is a cosmetic composition, characterized in that the formulation selected from the group consisting of hair tonic, hair nourishing lotion, scalp treatment, hair treatment, hair conditioner, hair shampoo and hair lotion.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200049883A KR102360927B1 (en) | 2020-04-24 | 2020-04-24 | Composition for preventing hair loss and promoting hair growth comprising runcinatside |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200049883A KR102360927B1 (en) | 2020-04-24 | 2020-04-24 | Composition for preventing hair loss and promoting hair growth comprising runcinatside |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210131597A true KR20210131597A (en) | 2021-11-03 |
KR102360927B1 KR102360927B1 (en) | 2022-02-09 |
Family
ID=78505032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200049883A KR102360927B1 (en) | 2020-04-24 | 2020-04-24 | Composition for preventing hair loss and promoting hair growth comprising runcinatside |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102360927B1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100247563A1 (en) * | 2009-03-30 | 2010-09-30 | Mary Kay Inc. | Topical skin care formulations |
US20190060389A1 (en) * | 2006-01-19 | 2019-02-28 | Mary Kay Inc. | Compositions comprising kakadu plum extract or acai berry extract |
JP6770968B2 (en) * | 2015-03-05 | 2020-10-21 | ルブリゾル アドバンスド マテリアルズ, インコーポレイテッド | Fermented extract of Eupenicillium crustaceum and its cosmetic use |
-
2020
- 2020-04-24 KR KR1020200049883A patent/KR102360927B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190060389A1 (en) * | 2006-01-19 | 2019-02-28 | Mary Kay Inc. | Compositions comprising kakadu plum extract or acai berry extract |
US20100247563A1 (en) * | 2009-03-30 | 2010-09-30 | Mary Kay Inc. | Topical skin care formulations |
JP6770968B2 (en) * | 2015-03-05 | 2020-10-21 | ルブリゾル アドバンスド マテリアルズ, インコーポレイテッド | Fermented extract of Eupenicillium crustaceum and its cosmetic use |
Also Published As
Publication number | Publication date |
---|---|
KR102360927B1 (en) | 2022-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101434653B1 (en) | Novel use of flavon compounds | |
JP5714869B2 (en) | Sugar-free pineapple extract, method for producing the same, and use thereof | |
KR102153414B1 (en) | Composition for improving hair loss and promoting hair growth containing a fermented soybean | |
KR102022622B1 (en) | Composition for improving skin conditions comprising panax ginseng sprout extract or fraction thereof and method for improving skin conditions using the same | |
JP6709783B2 (en) | Composition for preventing hair loss or promoting hair growth containing alpine wormwood extract | |
KR101283849B1 (en) | Novel cosmetic composition having antioxidant activity and skin-whitening effect | |
KR101824497B1 (en) | Composition comprising Phytoestrogen for preventing loss of hair and promoting growth of hair | |
JP6055667B2 (en) | Collagen production promoter | |
JP6647292B2 (en) | Composition for preventing hair loss or promoting hair growth comprising Scutellaria alpina extract | |
US20240115642A1 (en) | Composition for preventing hair loss or promoting hair growth comprising milk thistle flower extract as an active ingredient | |
KR102360927B1 (en) | Composition for preventing hair loss and promoting hair growth comprising runcinatside | |
KR102557372B1 (en) | Composition for Preventing or Treating Hair Loss or Stimulating Hair Sprouting or Hair Growth Comprising Extracts of Rosa davurica Pall as Active Ingredient | |
KR102435396B1 (en) | Composition for preventing hair loss and promoting hair growth comprising isoprostanoids | |
EP3127547B1 (en) | Composition comprising extract of alpine wormwood | |
KR20210134589A (en) | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom | |
KR20210131598A (en) | Composition for preventing hair loss or promoting hair growth, comprising Camellia japonica pericarp extract as an active ingredient | |
KR102047461B1 (en) | Composition for improving wrinkle comprising Symplocarpus foetidus extract or fractions thereof | |
KR20190130543A (en) | Composition for improving wrinkle comprising Symplocarpus foetidus extract or fractions thereof | |
KR20210025155A (en) | Composition for preventing hair loss or promoting hair growth comprising extract pupae of male bees | |
KR102276483B1 (en) | Composition for Preventing or Treating Hair Loss or Stimulating Hair Sprouting or Hair Growth Comprising Complex Extracts of Prunellae spica, Polygonum cuspidata, and Cnidium officinale as an Active Ingredient | |
KR102625769B1 (en) | A composition for preventing, treating or improving hair loss comprising Rhynchosia Nulubilis extract and Polygonum Multiflorum extract and use thereof | |
KR102600558B1 (en) | Composition for promoting hair growth and preventing hair loss comprising atraric acid | |
KR102411893B1 (en) | Composition for inhibiting sebum secretion comprising Chestnut bur extract as an active ingredient | |
KR102078412B1 (en) | Composition Comprising an Extract of Hwanggeumchal Sorghum, or Fractions thereof for Preventing Hair Loss or Promoting Hair Growth | |
KR101937433B1 (en) | Composition for the preventing loss of hair and promoting growth of hair containing benzofuran derivative or pharmaceutically acceptable salts thereof as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right |